The board's only other member is CEO and cofounder Anne Wojcicki. "I am excited to welcome these three experienced directors to the 23andMe Board, and looking forward to working with them ...

The genetic testing company 23andMe has agreed to pay $30 million to American plaintiffs to settle a lawsuit over a data breach last year that specifically targeted customers of Ashkenazi Jewish ...

The Osteoporosis PRS report was developed by 23andMe scientists and clinical experts using 23andMe's database of genetic and ...

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

23andMe faced major hurdles in 2024 ... made strides with its new preventive care membership service, signed a $20 million research agreement with biopharma company GSK, and saw "repeated ...

recently announcing a weight-loss membership programme focused on GLP-1 drugs. Despite those efforts, 23andMe's revenue growth has shifted into reverse in recent years – down 33% in the third ...

When evaluating 23andMe's stock performance and future outlook, investors should consider short-term market trends and long-term growth potential. This analysis will dive into recent stock metrics ...

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human ...

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...